Journal
BONE MARROW TRANSPLANTATION
Volume 43, Issue 11, Pages 821-828Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2009.63
Keywords
mesenchymal; stromal; stem cell; autoimmune disease; scleroderma; multiple sclerosis
Categories
Funding
- Fondazione Italiana Sclerosi Multipla (FISM)
- Italian Ministry of Health
- Ricerca Finalizzata, the Italian Ministry of the University and Scienti. c Research (MIUR)
- Fondazione CARIGE
- Fondazione CARIPLO
Ask authors/readers for more resources
MSCs, otherwise known as multipotent mesenchymal stromal cells, are being examined for the treatment of autoimmune disease (AD) on the basis of their in vitro antiproliferative properties, efficacy in animal models, apparent low acute toxicity and the early positive anecdotal outcomes in human acute GVHD. Phase I/II clinical trials are underway in Crohn's disease and multiple sclerosis (MS) and are being planned for systemic lupus erythematosus (SLE), systemic sclerosis (SSc), systemic vasculitis and other AD. Open issues include patient selection, disease stage and activity, MSC source and expansion and long-term safety. Multidisciplinary groups are collaborating to ensure maximal use of available resources to establish the place, if any, of MSC in the treatment of AD. Bone Marrow Transplantation (2009) 43, 821-828; doi: 10.1038/bmt.2009.63; published online 23 March 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available